Skip to content

Bioventus

US · BVS #3345 by market cap Listed 2021
9.88 -0.07 -0.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 9.85 -1.01%
After-hours 9.88 0.00%
15.267.939.882026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BVS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +10.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 4.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A
ValuationGrowthProfitMomentumHealthAnalyst
Valuation B

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 12.2x Better than 70%
Forward P/E 20.8x Better than 34%
Price / Sales 1.2x Better than 72%
P/E vs own 5-yr range 65th pctl Better than 44%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 3.5% Better than 41%
Free cash flow CAGR (3Y) 162.0% Better than 97%
Profitability B

How much profit the business keeps from each dollar of sales and capital.

Gross margin 68.3% Better than 82%
Operating margin 9.9% Better than 51%
Net margin 4.0% Better than 40%
Return on equity 13.7% Better than 64%
Return on invested capital 8.8% Better than 64%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -31.3% Better than 17%
6-month return 6.5% Better than 67%
12-month return (ex latest month) 107.7% Better than 96%
Distance below 52-week high 37.8% Better than 31%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.7x Better than 48%
Debt to assets 43.0% Better than 23%
Interest coverage 2.0x Better than 36%
Free cash flow / net income 317.2% Better than 87%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 68.7% Better than 76%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.32%
1M -29.18%
3M -31.05%
6M -9.69%
YTD +32.80%
1Y +51.30%
3Y +155.96%
5Y -29.53%

Key statistics

Price & volume

Prev close
9.95
Open
9.85
Day range
9.81 - 10.17
Avg price
9.90
Volume
612.44K
Turnover
6.06M
Amplitude
3.62%
52-week range
7.02 - 15.89

Valuation

P/E
29.94
P/E (TTM)
12.20
P/B
2.81
EPS
0.33
Net profit
22.60M
Net assets
240.48M

Share structure

Market cap
676.53M
Float cap
330.71M
Shares out
68.47M
Float shares
33.47M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-02-11
52-week range 32% of range
7.02 15.89

37.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.19M net over the window

Short interest

Shares short
3.02M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Bioventus (BVS)?

Bioventus last traded at 9.88. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Bioventus's market cap?

About 676.53M.

What is the P/E ratio of Bioventus?

The trailing twelve-month P/E is 12.20, below its own 5-year average of 32.69 — in the middle of its historical range (64.96% percentile). See the Valuation tab for the full history.

Does Bioventus pay a dividend?

Bioventus does not currently pay a regular dividend.

Is Bioventus a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 16.67, which implies 68.7% upside from the current price. This is not investment advice.

What is Bioventus's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Bioventus a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Bioventus discussion 0 comments

Add a comment